Aug 25, 2024

Mabwell Announces CDE Approval to Initiate Phase III Clinical Trial of 9MW2821 for Urothelial Carcinoma in Combination with PD-1 Inhibitor

➞

Aug 22, 2024

Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC to Initiate Phase III Clinical Trial for the Treatment of Cervical Cancer

➞

Aug 11, 2024

Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Granted Breakthrough Therapy Designation by CDE of NMPA

➞

Aug 05, 2024

Mabwell Inks Licensing and Commercialization Agreement for Denosumab Biosimilars in Brazil

➞

Aug 02, 2024

Mabwell Expands Bone Health Pipeline with In-licensing of RP901, a Potential First-in-Class Therapy

➞

Jul 16, 2024

FDA Grants Orphan Drug Designation to 7MW3711

➞

Jul 15, 2024

Mabwell Receives NMPA Approval for Clinical Trial of Novel Nectin-4 Targeting ADC in TNBC

➞

Jul 12, 2024

FDA Grants Fast Track Designation to 9MW2821 for the Treatment of Patients with Locally Advanced or Metastatic Nectin-4 Positive TNBC

➞

Jun 05, 2024

Multi-Indication Efficacy of Mabwell's 9MW2821 Highlighted in Oral Presentation at 2024 ASCO

➞

May 24, 2024

Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual Meeting

➞